BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Erez A, Shchelochkov OA, Plon SE, Scaglia F, Lee B. Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. Am J Hum Genet 2011;88:402-21. [PMID: 21473982 DOI: 10.1016/j.ajhg.2011.03.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Bruckman KC, Napoli JA, Diecidue RJ, Gold L. Facial dysmorphology and odontogenic tumor development associated with inborn errors of metabolism: a case report. J Oral Maxillofac Surg 2015;73:274-83. [PMID: 25579010 DOI: 10.1016/j.joms.2014.08.038] [Reference Citation Analysis]
2 Inui A, Hashimoto T, Sogo T, Komatsu H, Saheki T, Fujisawa T. Chronic hepatitis without hepatic steatosis caused by citrin deficiency in a child: Chronic hepatitis in pre-CTLN2. Hepatol Res 2016;46:357-62. [DOI: 10.1111/hepr.12559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
3 Gallagher RC, Lam C, Wong D, Cederbaum S, Sokol RJ. Significant hepatic involvement in patients with ornithine transcarbamylase deficiency. J Pediatr. 2014;164:720-725.e6. [PMID: 24485820 DOI: 10.1016/j.jpeds.2013.12.024] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
4 Piccolo P, Rossi A, Brunetti-Pierri N. Liver-directed gene-based therapies for inborn errors of metabolism. Expert Opin Biol Ther 2021;21:229-40. [PMID: 32880494 DOI: 10.1080/14712598.2020.1817375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Maleki Dizaj S, Alipour M, Dalir Abdolahinia E, Ahmadian E, Eftekhari A, Forouhandeh H, Rahbar Saadat Y, Sharifi S, Zununi Vahed S. Curcumin nanoformulations: Beneficial nanomedicine against cancer. Phytother Res 2022. [PMID: 35129230 DOI: 10.1002/ptr.7389] [Reference Citation Analysis]
6 Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog 2013;18:235-46. [PMID: 23510066 DOI: 10.1615/critrevoncog.2013006145] [Cited by in Crossref: 61] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
7 DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 2012;148:1132-44. [PMID: 22424225 DOI: 10.1016/j.cell.2012.02.032] [Cited by in Crossref: 430] [Cited by in F6Publishing: 398] [Article Influence: 43.0] [Reference Citation Analysis]
8 Park J, Park J, Pei Y, Xu J, Yeo Y. Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. Adv Drug Deliv Rev 2016;104:93-109. [PMID: 26686832 DOI: 10.1016/j.addr.2015.12.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
9 Zengeya TT, Garlick JM, Kulkarni RA, Miley M, Roberts AM, Yang Y, Crooks DR, Sourbier C, Linehan WM, Meier JL. Co-opting a Bioorthogonal Reaction for Oncometabolite Detection. J Am Chem Soc 2016;138:15813-6. [PMID: 27960310 DOI: 10.1021/jacs.6b09706] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
10 Cheng L, Liu Y, Wang W, Merritt JL, Yeh M. Hepatocellular Adenoma in a Patient with Ornithine Transcarbamylase Deficiency. Case Reports Hepatol 2019;2019:2313791. [PMID: 31662921 DOI: 10.1155/2019/2313791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Cucchetti A, Cescon M, Trevisani F, Pinna AD. Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol 2012; 18(44): 6398-6408 [PMID: 23197885 DOI: 10.3748/wjg.v18.i44.6398] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
12 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 201] [Article Influence: 36.3] [Reference Citation Analysis]
13 Shi ZH, Shi FF, Wang YQ, Sheftel AD, Nie G, Zhao YS, You LH, Gou YJ, Duan XL, Zhao BL, Xu HM, Li CY, Chang YZ. Mitochondrial ferritin, a new target for inhibiting neuronal tumor cell proliferation. Cell Mol Life Sci 2015;72:983-97. [PMID: 25213357 DOI: 10.1007/s00018-014-1730-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
14 Wishart DS. Metabolomics for Investigating Physiological and Pathophysiological Processes. Physiol Rev 2019;99:1819-75. [PMID: 31434538 DOI: 10.1152/physrev.00035.2018] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 32.7] [Reference Citation Analysis]
15 Berendse K, Koot BGP, Klouwer FCC, Engelen M, Roels F, Lacle MM, Nikkels PGJ, Verheij J, Poll-The BT. Hepatic symptoms and histology in 13 patients with a Zellweger spectrum disorder. J Inherit Metab Dis 2019;42:955-65. [PMID: 31150129 DOI: 10.1002/jimd.12132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Erez A, DeBerardinis RJ. Metabolic dysregulation in monogenic disorders and cancer - finding method in madness. Nat Rev Cancer 2015;15:440-8. [PMID: 26084394 DOI: 10.1038/nrc3949] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
17 Narayanan P, Mistry PK. Update on Alpha-1 Antitrypsin Deficiency in Liver Disease. Clin Liver Dis (Hoboken). 2020;15:228-235. [PMID: 32617155 DOI: 10.1002/cld.896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Chen MA, Weinstein DA. Glycogen storage diseases: Diagnosis, treatment and outcome. TRD 2016;1:45-72. [DOI: 10.3233/trd-160006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
19 Giunchedi P, Maestri M, Gavini E, Dionigi P, Rassu G. Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. Expert Opin Drug Deliv 2013;10:679-90. [PMID: 23406440 DOI: 10.1517/17425247.2013.770733] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
20 Ohnishi M, Higuchi A, Matsumura H, Arakawa Y, Nakamura H, Nirei K, Yamamoto T, Yamagami H, Ogawa M, Gotoda T, Matsuoka S, Nakajima N, Sugitani M, Moriyama M, Murayama H. Involvement of Ornithine Carbamoyltransferase in the Progression of Chronic Hepatitis C and Liver Cirrhosis. Int J Med Sci. 2017;14:629-638. [PMID: 28824294 DOI: 10.7150/ijms.17641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
21 Bigot A, Tchan MC, Thoreau B, Blasco H, Maillot F. Liver involvement in urea cycle disorders: a review of the literature. J Inherit Metab Dis. 2017;40:757-769. [PMID: 28900784 DOI: 10.1007/s10545-017-0088-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
22 Chong SC, Lo P, Chow CW, Yuen L, Chu WCW, Leung TY, Hui J, Scaglia F. Molecular and clinical characterization of citrin deficiency in a cohort of Chinese patients in Hong Kong. Mol Genet Metab Rep 2018;17:3-8. [PMID: 30181955 DOI: 10.1016/j.ymgmr.2018.08.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
23 Harris AN, Hinojosa BR, Chavious MD, Petros RA. Beyond platinum: synthesis, characterization, and in vitro toxicity of Cu(II)-releasing polymer nanoparticles for potential use as a drug delivery vector. Nanoscale Res Lett 2011;6:445. [PMID: 21745364 DOI: 10.1186/1556-276X-6-445] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
24 Feng T, Wei Y, Lee RJ, Zhao L. Liposomal curcumin and its application in cancer. Int J Nanomedicine 2017;12:6027-44. [PMID: 28860764 DOI: 10.2147/IJN.S132434] [Cited by in Crossref: 108] [Cited by in F6Publishing: 57] [Article Influence: 21.6] [Reference Citation Analysis]
25 Jerves T, Blau N, Ferreira CR. Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias. Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.03.011] [Reference Citation Analysis]
26 Wilson JM, Shchelochkov OA, Gallagher RC, Batshaw ML. Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. Mol Genet Metab. 2012;105:263-265. [PMID: 22129577 DOI: 10.1016/j.ymgme.2011.10.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
27 Wang KX, Chen YP, Lu AP, Du GH, Qin XM, Guan DG, Gao L. A metabolic data-driven systems pharmacology strategy for decoding and validating the mechanism of Compound Kushen Injection against HCC. J Ethnopharmacol 2021;274:114043. [PMID: 33753143 DOI: 10.1016/j.jep.2021.114043] [Reference Citation Analysis]
28 Chanprasert S, Scaglia F. Adult liver disorders caused by inborn errors of metabolism: review and update. Mol Genet Metab 2015;114:1-10. [PMID: 25467056 DOI: 10.1016/j.ymgme.2014.10.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
29 Potter SL, Venkatramani R, Wenderfer S, Graham BH, Vasudevan SA, Sher A, Wu H, Wheeler DA, Yang Y, Eng CM, Gibbs RA, Roy A, Plon SE, Parsons DW. Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia. Pediatr Blood Cancer 2017;64. [PMID: 27748010 DOI: 10.1002/pbc.26286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Ozawa MG, Cooney T, Rangaswami A, Hazard FK. Synchronous Hepatoblastoma, Neuroblastoma, and Cutaneous Capillary Hemangiomas: A Case Report. Pediatr Dev Pathol 2016;19:74-9. [PMID: 26368548 DOI: 10.2350/14-11-1573-CR.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]